- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00763022
Efficacy of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Study of the Safety and Efficacy of TAK-559 Compared to Placebo in the Treatment of Patients With Type 2 Diabetes Mellitus
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Insulin is a primary regulator of blood glucose concentrations. A subnormal response to circulating insulin levels at target tissues leads to a decrease in insulin-mediated glucose uptake. Insulin resistance is associated with normal to high insulin levels and is often accompanied by dyslipidemia, a disruption in lipid metabolism resulting in increased triglycerides and low-density lipoprotein levels as well as decreased high-density lipoprotein levels in patients with type 2 diabetes mellitus. In the early stages of insulin resistance, a compensatory mechanism of increased insulin secretion by the pancreas maintains normal to near-normal glucose levels. Once the pancreas fails to maintain the increased insulin output, overt type 2 diabetes mellitus occurs.
TAK-559 is a novel oxyiminoalkanoic acid under investigation for use as an oral agent in the treatment of patients with type 2 diabetes mellitus. TAK-559 has partial peroxisome proliferator-activated receptor-alpha agonist activity, potent peroxisome proliferator-activated receptor-alpha activity, and modest peroxisome proliferator-activated receptor-gamma activity at high concentrations in nonclinical models.
This study was designed to evaluate the safety and glycemic control of TAK-559 in patients with type 2 diabetes mellitus whose symptoms were managed by diet and exercise.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Is diagnosed with type 2 diabetes mellitus using American Diabetes Association diagnostic criteria, and on a stable dose of an oral anti-diabetic monotherapy prior to Screening A.
- Had a glycosylated hemoglobin level greater than or equal to 8.0% and less than or equal to 10.0% at Screening B.
- Had a fasting plasma glucose greater than or equal to 126 mg/dL (7.0 mmol/L) at Screening B.
- Was taking a stable dose of at least 10 mg of glyburide for at least 10 days prior to Screening B.
- Was on a stable or worsening self-monitoring blood glucose level while taking glyburide.
- Had a low-density lipoprotein less than 160 mg/dL (4.1 mmol/L) at Screening A.
- Had a body mass index less than or equal to 45 kg/m2 at Screening A.
- Was willing to be counseled by the investigator or designee to follow an individualized, weight-maintaining diet during the study period.
- Had evidence of insulin secretory capacity as demonstrated by a C-peptide concentration of greater than or equal to 1.5 ng/mL (0.50 nmol/L) at Screening A, and if necessary, after a repeat at Screening B.
- Was able to perform daily self-monitoring blood glucose tests throughout the study.
- Had a normal thyroid-stimulating hormone level of less than 5.5 uIU/mL (5.5 mIU/L) and greater than or equal to 0.35 uIU/mL (0.35 mIU/L) at Screening A.
- Was in good health as determined by a physician (ie, via medical history and physical examination), other than a diagnosis of type 2 diabetes mellitus.
- Had fasting clinical laboratory evaluations within the normal reference range for the testing laboratory, or if not, the results must be deemed not clinically significant by the investigator prior to Randomization.
- Females were post menopausal, surgically sterile, or using adequate contraception.
Exclusion Criteria:
- Was diagnosed with type 1 diabetes mellitus, hemochromatosis, or has a history of ketoacidosis.
- Had any condition known to invalidate glycosylated hemoglobin results (eg, hemolytic states, hemoglobinopathies).
Was required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:
- Insulin
- Oral anti-diabetics other than TAK-559 (including sulfonylureas other than glyburide, alpha-glucosidase inhibitors, metformin)
- Systemic corticosteroids
- Warfarin
- Rifampin
- St. John's Wort.
- Thiazolidinediones
- Peroxisome proliferator-activated receptor agonists
- Nicotinic Acid
- Fibrates
- Had a history of myocardial infarction, coronary angioplasty or bypass graft, unstable angina pectoris, transient ischemic attacks, clinically significant abnormal electrocardiogram, or documented cerebrovascular accident within 6 months prior to Screening A.
- Had abdominal, thoracic, or vascular surgery within 6 months prior to Screening A that in the investigator's opinion would warrant exclusion from the study.
- Had a creatine phosphokinase value greater than 3 times the upper limit of normal at Screening A. The creatine phosphokinase value can be retested prior to Randomization if elevated.
- Had persistent unexplained microscopic or macroscopic hematuria or a history of bladder cancer.
- Had a triglyceride level greater than 500 mg/dL (5.6 mmol/L) at Screening A.
- Had any alteration in allowed lipid lowering medication (dose or drug) within 2 months of Randomization, if applicable.
- Had donated and/or received any blood or blood products within 3 months prior to Randomization.
- Had a history of drug abuse (defined as illicit drug use) or a history of alcohol abuse (defined as regular or daily consumption of more than 4 alcoholic drinks per day) within 2 years prior to Randomization.
- Had a systolic BP greater than 140 mm Hg or a diastolic blood pressure of greater than 95 mm Hg at Screening B.
- Had significant cardiovascular disease including but not limited to, New York Heart Association Functional (Cardiac) Classification III or IV.
- Had a previous history of cancer, other than basal cell or stage 1 squamous cell carcinoma of the skin, that has not been in remission within 5 years prior to Randomization.
- Had an alanine transaminase or aspartate transaminase level greater than 3 times the upper limit of normal, active liver disease, or jaundice at Screening A.
- Had a positive human immunodeficiency virus, hepatitis B surface antigen, or hepatitis B e antigen test at Screening A.
- Had any other serious disease or condition at Screening A or at Randomization that might affect life expectancy or make it difficult to successfully manage and follow the patient according to the protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Placebo QD
|
TAK-559 placebo-matching tablets, orally, once daily for up to 26 weeks.
|
EXPERIMENTAL: TAK-559 16 mg QD
|
TAK-559 16 mg, tablets, orally, once daily for up to 26 weeks.
TAK-559 32 mg, tablets, orally, once daily for up to 26 weeks.
|
EXPERIMENTAL: TAK-559 32mg QD
|
TAK-559 16 mg, tablets, orally, once daily for up to 26 weeks.
TAK-559 32 mg, tablets, orally, once daily for up to 26 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in Baseline in Glycosylated hemoglobin.
Time Frame: Weeks: 4, 8, 12, 16, 20 and Final Visit.
|
Weeks: 4, 8, 12, 16, 20 and Final Visit.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in Baseline in Glycosylated hemoglobin.
Time Frame: Weeks: 4, 8, 12, 16, 20 and Final Visit.
|
Weeks: 4, 8, 12, 16, 20 and Final Visit.
|
Change in Baseline in Fasting Plasma Glucose.
Time Frame: Weeks: 2, 4, 8, 12, 16, 20 and Final Visit.
|
Weeks: 2, 4, 8, 12, 16, 20 and Final Visit.
|
Change in Baseline in Serum insulin.
Time Frame: Weeks: 4, 12, 16, 20 and Final Visit.
|
Weeks: 4, 12, 16, 20 and Final Visit.
|
Change in Baseline in C-peptide.
Time Frame: Weeks: 4, 12, 16, 20 and Final Visit.
|
Weeks: 4, 12, 16, 20 and Final Visit.
|
Change in Baseline in Lipids (triglycerides, total cholesterol, high-density lipoprotein, low-density lipoprotein, very-low-density lipoprotein).
Time Frame: Weeks: 12, 16, 20 and Final Visit.
|
Weeks: 12, 16, 20 and Final Visit.
|
Change in Baseline in Lipids (low-density lipoprotein fractionation).
Time Frame: Weeks: 12, 16, 20 and Final Visit.
|
Weeks: 12, 16, 20 and Final Visit.
|
Change in Baseline in Apolipoproteins Al and B100.
Time Frame: Final Visit.
|
Final Visit.
|
Change in Baseline in Free fatty acids.
Time Frame: Weeks: 12, 16, 20 and Final Visit.
|
Weeks: 12, 16, 20 and Final Visit.
|
Markers of thrombosis (plasminogen activator inhibitor-i).
Time Frame: Weeks: 4, 12, 16, 20 and Final Visit.
|
Weeks: 4, 12, 16, 20 and Final Visit.
|
Markers of thrombosis (fibrinogen).
Time Frame: Weeks: 4, 12, 16, 20 and Final Visit.
|
Weeks: 4, 12, 16, 20 and Final Visit.
|
Markers of inflammation (interleukin-6).
Time Frame: Weeks: 4, 12, 16, 20 and Final Visit.
|
Weeks: 4, 12, 16, 20 and Final Visit.
|
Markers of inflammation (C-reactive protein).
Time Frame: Weeks: 4, 12, 16, 20 and Final Visit.
|
Weeks: 4, 12, 16, 20 and Final Visit.
|
Urinary albumin/creatinine ratio.
Time Frame: Weeks: 12, 16, 20 and Final Visit.
|
Weeks: 12, 16, 20 and Final Visit.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 01-02-TL-559-014
- U1111-1127-8487 (REGISTRY: WHO)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
Meir Medical CenterCompletedDiabetes Mellitus Type 2 | Diabetes Mellitus, Non-insulin Dependant | Diabetes Mellitus, on Oral Hypoglycemic Treatment | Adult Type Diabetes MellitusIsrael
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
Medical College of WisconsinMedical University of South CarolinaCompletedDiabetes Mellitus | Type 2 Diabetes Mellitus | Adult-Onset Diabetes Mellitus | Non-Insulin-Dependent Diabetes Mellitus | Noninsulin Dependent Diabetes Mellitus, Type IIUnited States
-
Hanmi Pharmaceutical Company LimitedUnknownType2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Medical College of WisconsinMedical University of South Carolina; National Institute of Diabetes and Digestive...Active, not recruitingDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Medical College of WisconsinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Joslin Diabetes CenterCambridge Medical Technologies, LLCCompletedType 2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
Clinical Trials on TAK-559
-
TakedaTerminated
-
TakedaTerminated
-
TakedaTerminated
-
TakedaTerminatedDiabetes Mellitus
-
TakedaTerminated
-
MedImmune LLCCompletedHealthyUnited States, Puerto Rico
-
TakedaWithdrawn